Table 2. Factors Associated with Positive HBV Vaccine Seroresponse for HIV Controllers Compared to Non-controllers With or Without Viral Load-Suppressive HAART.

Characteristic	HIV Controllers vsHAART-naïve Non-Controllers (OR, 95% CI)	P-value	HIV Controllers vs Non-Controllers on HAART(OR, 95% CI)	P-value
HIV Controller vs Non-Controller	2.65 (1.23–5.89)	0.014	1.16 (0.53–2.6)	0.718
African-American vs Caucasian	0.89 (0.54–1.47)	0.662	1.38 (0.79–2.41)	0.256
Hispanic/Other vs Caucasian	1.76 (0.91–3.4)	0.091	0.93 (0.43–2.02)	0.847
Female vs Male	1.44 (0.75–2.75)	0.269	1.14 (0.56–2.38)	0.717
Age at Last Vaccination(Per 10 years)	0.75 (0.54–1.04)	0.087	0.98 (0.76–1.26)	0.884
CD4 Count at Last Vaccination(For Every 100 Cells/uL)	1.28 (1.15–1.45)	<0.001	1.23 (1.1–1.38)	<0.001
Number of Vaccine Doses,≥3 vs 1–2	0.56 (0.35–0.88)	0.011	1.11 (0.66–1.86)	0.693
AIDS Before Last Vaccination	0.84 (0.45–1.52)	0.567	1.63 (0.91–3.0)	0.107

HBV, hepatitis B virus; HAART, highly active antiretroviral therapy; OR, odds ratio; CI, confidence interval; AIDS, acquired immunodeficiency syndrome.

Data are number (%) or median (Interquartile Range).

Positive HBV vaccine seroresponse defined as antibody to HBV surface antigen ≥10 IU/L measured ≥1 month after last HBV vaccination.